Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD300 molecule-like family member F (CD300lf), also known as IREM-1, is a type I transmembrane glycoprotein primarily expressed on myeloid lineage cells such as monocytes, macrophages, and neutrophils (UniProt Q8TDQ1). It belongs to the CD300 family of immunoregulatory receptors and contains extracellular immunoglobulin-like domains and cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) (Zenarruzabeitia et al., 2015). CD300lf functions as a rheostat for immune activation by recognizing ligands like phosphatidylserine and ceramide, which are exposed on apoptotic cells, thereby mediating efferocytosis and suppressing pro-inflammatory cytokine production (Simhadri et al., 2011). Beyond its role in homeostasis, CD300lf has gained significant attention as the essential cellular receptor for murine norovirus, where it dictates viral tropism and entry (Orchard et al., 2016). In drug development, CD300lf is considered a potential therapeutic target for treating inflammatory disorders and certain malignancies by modulating myeloid cell-mediated immunity. However, its broad expression across various immune cell subsets poses challenges for achieving cell-specific therapeutic effects without systemic toxicity.
Modulation of myeloid cell activation through ITIM-mediated inhibitory signaling and blockade of viral entry by preventing receptor-ligand interaction (Orchard et al., 2016; Zenarruzabeitia et al., 2015).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD300 molecule-like family member F (CD300lf) (CD300lf).